ATE240104T1 - Cyclodextrine als suspendiermittel für pharmazeutische suspensionen - Google Patents
Cyclodextrine als suspendiermittel für pharmazeutische suspensionenInfo
- Publication number
- ATE240104T1 ATE240104T1 AT95941473T AT95941473T ATE240104T1 AT E240104 T1 ATE240104 T1 AT E240104T1 AT 95941473 T AT95941473 T AT 95941473T AT 95941473 T AT95941473 T AT 95941473T AT E240104 T1 ATE240104 T1 AT E240104T1
- Authority
- AT
- Austria
- Prior art keywords
- cyclodextrins
- suspensions
- pharmaceutical suspensions
- stabilized
- suspending agents
- Prior art date
Links
- 229920000858 Cyclodextrin Polymers 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 title 1
- 229940097362 cyclodextrins Drugs 0.000 title 1
- 239000007971 pharmaceutical suspension Substances 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 239000000375 suspending agent Substances 0.000 abstract 2
- 239000000725 suspension Substances 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 239000007900 aqueous suspension Substances 0.000 abstract 1
- 238000010668 complexation reaction Methods 0.000 abstract 1
- 239000003246 corticosteroid Substances 0.000 abstract 1
- 229960001334 corticosteroids Drugs 0.000 abstract 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract 1
- 230000007928 solubilization Effects 0.000 abstract 1
- 238000005063 solubilization Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cephalosporin Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/346,954 US5576311A (en) | 1994-11-30 | 1994-11-30 | Cyclodextrins as suspending agents for pharmaceutical suspensions |
| PCT/US1995/015348 WO1996016659A1 (en) | 1994-11-30 | 1995-11-28 | Cyclodextrins as suspending agents for pharmaceutical suspensions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE240104T1 true ATE240104T1 (de) | 2003-05-15 |
Family
ID=23361723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT95941473T ATE240104T1 (de) | 1994-11-30 | 1995-11-28 | Cyclodextrine als suspendiermittel für pharmazeutische suspensionen |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US5576311A (de) |
| EP (1) | EP0794783B1 (de) |
| JP (1) | JPH10510532A (de) |
| AT (1) | ATE240104T1 (de) |
| AU (1) | AU715895B2 (de) |
| CA (1) | CA2206348A1 (de) |
| DE (1) | DE69530785T2 (de) |
| WO (1) | WO1996016659A1 (de) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5849263A (en) * | 1993-03-30 | 1998-12-15 | Charlotte-Mecklenburg Hospital Authority | Pharmaceutical compositions containing alkylaryl polyether alcohol polymer |
| WO1996022088A1 (en) * | 1995-01-20 | 1996-07-25 | Wakamoto Pharmaceutical Co., Ltd. | Anti-inflammatory eyedrops |
| US5942501A (en) * | 1996-08-16 | 1999-08-24 | Collaborative Laboratories, Inc. | Cyclodextrin derivative complex |
| EP0834308A1 (de) * | 1996-09-30 | 1998-04-08 | LG Chemical Limited | Ophthalmische Zubereitung zur Behandlung von Kurzsichtigkeit enthaltend einen Dopaminagonisten und Cyclodextrin |
| EP0938896A1 (de) | 1998-01-15 | 1999-09-01 | Novartis AG | In Autoklaven behandelbare pharmazeutische Zusammensetzungen mit Komplexbildner |
| JP2002523475A (ja) * | 1998-09-02 | 2002-07-30 | アラーガン・セイルズ・インコーポレイテッド | 防腐したシクロデキストリン含有組成物 |
| US6211246B1 (en) * | 1999-06-10 | 2001-04-03 | Mcneil-Ppc, Inc. | Rapidly absorbed liquid compositions |
| EP1305637A2 (de) * | 2000-08-02 | 2003-05-02 | Malope Company Limited | Diagnose und behandlung nichtulzerativer dyspepsie auf basis von abnormalitäten der hypothalamus-hypophise-adrenal-achse |
| US20030044356A1 (en) * | 2001-04-20 | 2003-03-06 | Jin Auh | Composition for nasal solution sprays having effective component of 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one) |
| US20040214797A1 (en) * | 2001-05-07 | 2004-10-28 | Allergan, Inc. | Preserved pharmaceutical compositions comprising cyclodextrins |
| IL152573A (en) | 2002-10-31 | 2009-11-18 | Transpharma Medical Ltd | A system for the transmission through the skin of a medical preparation against vomiting and nausea |
| IL152575A (en) | 2002-10-31 | 2008-12-29 | Transpharma Medical Ltd | A skin-to-skin transmission system of water-insoluble drugs |
| US20070224278A1 (en) | 2003-11-12 | 2007-09-27 | Lyons Robert T | Low immunogenicity corticosteroid compositions |
| US20050101582A1 (en) | 2003-11-12 | 2005-05-12 | Allergan, Inc. | Compositions and methods for treating a posterior segment of an eye |
| US20050250737A1 (en) * | 2003-11-12 | 2005-11-10 | Allergan, Inc. | Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods |
| US20070020299A1 (en) | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| CN100548271C (zh) | 2004-01-20 | 2009-10-14 | 阿勒根公司 | 用于眼部的局部治疗、并优选包括有曲安奈德及透明质酸的组合物 |
| US20050234018A1 (en) * | 2004-04-15 | 2005-10-20 | Allergan, Inc. | Drug delivery to the back of the eye |
| US20050239747A1 (en) * | 2004-04-21 | 2005-10-27 | Pharmaceutical Industry Technology And Development Center | Compositions and methods of enhanced transdermal delivery of steroid compounds and preparation methods |
| US8147865B2 (en) | 2004-04-30 | 2012-04-03 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
| US8119154B2 (en) | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
| KR100649154B1 (ko) | 2004-06-01 | 2006-11-24 | 명문제약주식회사 | 아세클로페낙의 가용화 방법 |
| EP1806129A1 (de) * | 2004-10-01 | 2007-07-11 | Eisai R&D Management Co., Ltd. | Feine teilchen enthaltende zusammensetzung und verfahren zu ihrer herstellung |
| WO2006040839A1 (ja) * | 2004-10-15 | 2006-04-20 | Advanced Medicine Research Institute | 眼疾患処置用点眼剤及びキット |
| EP2336117A1 (de) | 2005-05-26 | 2011-06-22 | Neuron Systems, Inc | Heterozyklische Verbindungen zur Behandlung retinaler Erkrankungen |
| WO2007076448A2 (en) * | 2005-12-23 | 2007-07-05 | Alcon, Inc. | Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye |
| US20070238789A1 (en) * | 2006-03-31 | 2007-10-11 | Chin-Ming Chang | Prednisolone acetate compositions |
| US8668676B2 (en) * | 2006-06-19 | 2014-03-11 | Allergan, Inc. | Apparatus and methods for implanting particulate ocular implants |
| US20080097335A1 (en) * | 2006-08-04 | 2008-04-24 | Allergan, Inc. | Ocular implant delivery assemblies |
| US9744137B2 (en) | 2006-08-31 | 2017-08-29 | Supernus Pharmaceuticals, Inc. | Topiramate compositions and methods of enhancing its bioavailability |
| TWI415629B (zh) | 2006-10-26 | 2013-11-21 | Otsuka Pharma Co Ltd | 含有瑞巴匹特之水性醫藥懸浮物及其製造方法 |
| US8158609B1 (en) * | 2006-11-02 | 2012-04-17 | Novartis Ag | Use of cyclodextrins as an active ingredient for treating dry AMD and solubilizing drusen |
| EP2394643B1 (de) | 2006-11-17 | 2015-09-02 | Supernus Pharmaceuticals, Inc. | Topiramat-Formulierungen mit verzögerter Freisetzung |
| CN102114002B (zh) * | 2006-12-04 | 2016-05-11 | 苏佩努斯制药公司 | 托吡酯的增强的立即释放制剂 |
| US12370352B2 (en) | 2007-06-28 | 2025-07-29 | Cydex Pharmaceuticals, Inc. | Nasal and ophthalmic delivery of aqueous corticosteroid solutions |
| US8545554B2 (en) | 2009-01-16 | 2013-10-01 | Allergan, Inc. | Intraocular injector |
| WO2011072141A1 (en) | 2009-12-11 | 2011-06-16 | Neuron Systems, Inc. | Compositions and methods for the treatment of macular degeneration |
| CA2791278C (en) | 2010-02-25 | 2015-11-24 | The Johns Hopkins University | Sustained delivery of therapeutic agents to an eye compartment |
| WO2012039979A2 (en) | 2010-09-10 | 2012-03-29 | The Johns Hopkins University | Rapid diffusion of large polymeric nanoparticles in the mammalian brain |
| AU2013232297B2 (en) | 2012-03-16 | 2016-01-14 | The Johns Hopkins University | Controlled release formulations for the delivery of HIF-1 inhibitors |
| EP2825207B1 (de) | 2012-03-16 | 2020-08-19 | The Johns Hopkins University | Nichtlineare multiblock-copolymer-arzneimittelkonjugate zur verabreichung von wirkstoffen |
| HK1208162A1 (en) | 2012-05-03 | 2016-02-26 | Kala Pharmaceuticals, Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
| US11596599B2 (en) | 2012-05-03 | 2023-03-07 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| US9827191B2 (en) | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| WO2013166408A1 (en) | 2012-05-03 | 2013-11-07 | Kala Pharmaceuticals, Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
| CA2872519C (en) | 2012-05-04 | 2017-09-05 | The Johns Hopkins University | Lipid-based drug carriers for rapid penetration through mucus linings |
| JP2015524411A (ja) * | 2012-07-18 | 2015-08-24 | オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | エポキシケトン系プロテアソーム阻害剤のリポソーム組成物 |
| CA2898631C (en) | 2013-01-23 | 2023-06-13 | Aldeyra Therapeutics, Inc. | Toxic aldehyde related diseases and treatment |
| WO2014124006A1 (en) | 2013-02-05 | 2014-08-14 | The Johns Hopkins University | Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof |
| CA2974715C (en) | 2015-01-27 | 2020-05-05 | The Johns Hopkins University | Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces |
| CN108135907A (zh) | 2015-08-21 | 2018-06-08 | 奥尔德拉医疗公司 | 氘化化合物和其用途 |
| KR20170039347A (ko) * | 2015-10-01 | 2017-04-11 | 삼진제약주식회사 | 레바미피드를 함유하는 신규한 점안 조성물 및 이의 제조방법 |
| MX2018010292A (es) | 2016-02-28 | 2018-09-27 | Aldeyra Therapeutics Inc | Tratamiento de condiciones oculares alergicas con ciclodextrinas. |
| US11129823B2 (en) | 2016-05-09 | 2021-09-28 | Aldeyra Therapeutics, Inc. | Combination treatment of ocular inflammatory disorders and diseases |
| US10414732B2 (en) | 2017-03-16 | 2019-09-17 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| MX2020003425A (es) | 2017-10-10 | 2020-07-29 | Aldeyra Therapeutics Inc | Tratamiento de trastornos inflamatorios. |
| EP3833660A4 (de) | 2018-08-06 | 2022-05-11 | Aldeyra Therapeutics, Inc. | Polymorphe verbindungen und verwendungen davon |
| JP7505786B2 (ja) | 2018-09-25 | 2024-06-25 | アルデイラ セラピューティクス， インコーポレイテッド | ドライアイ疾患を処置するための製剤 |
| WO2020198064A1 (en) | 2019-03-26 | 2020-10-01 | Aldeyra Therapeutics, Inc. | Ophthalmic formulations and uses thereof |
| US12496279B2 (en) | 2019-04-11 | 2025-12-16 | The Johns Hopkins University | Nanoparticles for drug delivery to brain |
| US12098132B2 (en) | 2019-05-02 | 2024-09-24 | Aldeyra Therapeutics, Inc. | Process for preparation of aldehyde scavenger and intermediates |
| CA3137301A1 (en) | 2019-05-02 | 2020-11-05 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| CN113209370B (zh) * | 2020-01-21 | 2023-11-28 | 渼颜空间(河北)生物科技有限公司 | 可生物降解的注射填充物及其制备方法和其应用 |
| WO2021231792A1 (en) | 2020-05-13 | 2021-11-18 | Aldeyra Therapeutics, Inc. | Pharmaceutical formulations and uses thereof |
| CN111840641A (zh) * | 2020-08-31 | 2020-10-30 | 陈玉芝 | 聚左旋乳酸填充剂及其制备方法和应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2861920A (en) * | 1954-05-04 | 1958-11-25 | Upjohn Co | Therapeutic suspensions of steroids containing pvp and/or pva |
| US4710495A (en) * | 1980-07-10 | 1987-12-01 | Otsuka Pharmaceutical Co., Ltd. | Soft steroids having anti-inflammatory activity |
| US4383992A (en) * | 1982-02-08 | 1983-05-17 | Lipari John M | Water-soluble steroid compounds |
| DE3346123A1 (de) * | 1983-12-21 | 1985-06-27 | Janssen Pharmaceutica, N.V., Beerse | Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung |
| US4727064A (en) * | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| US4596795A (en) * | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
| US4727077A (en) * | 1985-02-20 | 1988-02-23 | Ishihara Sangyo Kaisha Ltd. | Benzoyl urea compounds, process for their production, and antitumorous compositions containing them |
| NL8801670A (nl) * | 1988-07-01 | 1990-02-01 | Walter Adrianus Josephus Johan | Farmaceutisch preparaat. |
| EP0399716B1 (de) * | 1989-05-24 | 1994-01-26 | Innovet, Inc. | Hypoallergene anästhesierende/hypnotische steroide Arzneizubereitung |
| IT1241417B (it) * | 1990-03-06 | 1994-01-14 | Vectorpharma Int | Composizioni terapeutiche a rilascio controllato di farmaci supportatisu polimeri reticolati e rivestiti con film polimerici,e loro processodi preparazione |
| FR2692168B1 (fr) * | 1992-06-16 | 1995-03-24 | Centre Nat Rech Scient | Préparation et utilisation de nouveaux systèmes colloïdaux dispersibles à base de cyclodextrine, sous forme de nanosphères. |
| FR2692167B1 (fr) * | 1992-06-16 | 1994-09-16 | Centre Nat Rech Scient | Préparation et application de nouveaux systèmes colloïdaux nanovésiculaires dispersibles à base de cyclodextrine, sous forme de nanocapsules. |
| US5540930A (en) * | 1993-10-25 | 1996-07-30 | Pharmos Corporation | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
-
1994
- 1994-11-30 US US08/346,954 patent/US5576311A/en not_active Expired - Lifetime
-
1995
- 1995-11-28 JP JP8518965A patent/JPH10510532A/ja active Pending
- 1995-11-28 AT AT95941473T patent/ATE240104T1/de not_active IP Right Cessation
- 1995-11-28 AU AU42883/96A patent/AU715895B2/en not_active Ceased
- 1995-11-28 CA CA002206348A patent/CA2206348A1/en not_active Abandoned
- 1995-11-28 EP EP95941473A patent/EP0794783B1/de not_active Expired - Lifetime
- 1995-11-28 WO PCT/US1995/015348 patent/WO1996016659A1/en not_active Ceased
- 1995-11-28 DE DE69530785T patent/DE69530785T2/de not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US5576311A (en) | 1996-11-19 |
| DE69530785D1 (de) | 2003-06-18 |
| EP0794783B1 (de) | 2003-05-14 |
| DE69530785T2 (de) | 2004-02-19 |
| EP0794783A1 (de) | 1997-09-17 |
| AU4288396A (en) | 1996-06-19 |
| CA2206348A1 (en) | 1996-06-06 |
| AU715895B2 (en) | 2000-02-10 |
| WO1996016659A1 (en) | 1996-06-06 |
| EP0794783A4 (de) | 1998-03-04 |
| JPH10510532A (ja) | 1998-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69530785D1 (de) | Cyclodextrine als suspendiermittel für pharmazeutische suspensionen | |
| CA2289202A1 (en) | Solid pharmaceutical formulations containing a physical mixture of sulfoalkyl ether cyclodextrin and a therapeutic agent | |
| ATE163853T1 (de) | Aminosteroide zur verwendung in der augenheilkunde | |
| ATE164855T1 (de) | Redoxsystem für auf das gehirn gerichtete arzneimittelabgabe | |
| ATE277929T1 (de) | Immunsuppressive wirkungen von pteridinderivaten | |
| CY1114919T1 (el) | Anti-mag ανθρωποποιημενα αντισωματα και οι χρησεις τους για την αντιμετωπιση του εγκεφαλικου επεισοδιου | |
| ATE217523T1 (de) | Loteprednoletabonat-suspension | |
| ATE195721T1 (de) | Lipopolyamine als transfectionsmittel und ihre pharmazeutischen anwendungen | |
| BR9915553A (pt) | Amidas de ácido antranìlico e seu emprego como medicamento | |
| NO970051L (no) | Vandige risperidon formuleringer | |
| BG101118A (en) | Therapeutical compounds | |
| RU94028890A (ru) | Композиции производных циклодекстрина, композиции, содержащие лекарство и производные циклодекстринов | |
| DE59611341D1 (de) | Verwendung von saccharid-konjugaten | |
| NO972980L (no) | Anvendelse av nebivolol som et anti-aterogent middel | |
| MXPA03010843A (es) | Uso de derivados con azetidinona en el tratamiento de enfermedad de alzheimer. | |
| ES2184293T3 (es) | Composiciones farmaceuticas administrables por via oral que comprenden una benzhidrilpiperazina y una ciclodextrina. | |
| ATE386507T1 (de) | Mikropartikel | |
| BR9915800A (pt) | Produto terapêutico para supressão dos ruìdos de ronco | |
| SE9701515D0 (sv) | Arrangemang vid hjulupphängning | |
| BR0010183A (pt) | Derivados de monofluoroalquila | |
| PT1067934E (pt) | Solucao anti-depressiva liquida oral | |
| NO973589L (no) | Medikament for behandling av tvangstanke-tvangshandlingsproblemer, sövnapne, seksuelle funksjonsforstyrrelser, emesi og reisesyke | |
| DK1000046T3 (da) | Piperazinderivater, der er aktive på den nedre urinvejskanal | |
| EA200100674A1 (ru) | Клатраты дегидроэпиандростерона и соответствующие фармацевтические композиции | |
| GR1001511B (el) | Στεροειδείς συν?έσεις. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |